PUBLISHER: Polaris Market Research | PRODUCT CODE: 1831711
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1831711
The molecular diagnostics market size is expected to reach USD 38.01 billion by 2034, according to a new study by Polaris Market Research. The report "Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology, By Application, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The molecular diagnostics market focuses on the use of molecular biology techniques to detect genetic material, proteins, or other specific biomarkers in a patient's sample, enabling precise diagnosis, prognosis, and monitoring of diseases. This market has grown significantly due to the increasing demand for accurate, rapid, and minimally invasive diagnostic methods that support personalized medicine. The rising prevalence of infectious diseases, cancer, and genetic disorders has accelerated the adoption of molecular diagnostics in clinical settings. Continuous advancements in technologies such as digital PCR, next-generation sequencing, and microarrays are improving test sensitivity, specificity, and turnaround times, enhancing clinical decision-making.
Growing awareness among healthcare providers and patients about early disease detection is driving wider usage in preventive care. The integration of AI and automation in testing platforms is streamlining workflows and reducing errors, improving efficiency in laboratories. Expansion of point-of-care molecular testing is making diagnostics more accessible and timely, particularly in urgent care situations. Increasing investments in research and development by diagnostic companies is leading to innovative assays and platforms with broader test menus. Industry trends include a shift toward decentralized testing models, growth in companion diagnostics for targeted therapies, and rising collaborations between diagnostic developers and pharmaceutical companies. Opportunities lie in expanding test portfolios to address emerging pathogens, leveraging digital health integration for remote diagnostics, and advancing multiplex testing to detect multiple conditions in a single run. The market is positioned for sustained growth as precision medicine continues to shape healthcare, demanding fast, accurate, and scalable diagnostic solutions.
By product, the reagents systems segment dominated the market with ~66% of the revenue share due to continuous demand for consumables in routine molecular diagnostic workflows.
Based on test location, the central laboratories segment held ~80% of the revenue share in 2024 due to their capability to process high testing volumes with advanced instrumentation and specialized expertise.
The North America molecular diagnostics market accounted for the largest revenue share of ~41% due to strong adoption of advanced molecular testing technologies, and supported by a well-established healthcare infrastructure.
The Asia Pacific market is expected to grow significantly during 2025-2034 due to increasing healthcare investments, rapid adoption of advanced diagnostic platforms, and the rising burden of chronic and infectious diseases.
A few global key players include Abbott; Agilent Technologies, Inc.; BD; BIOMERIEUX; Bio-Rad Laboratories, Inc.; Danaher; F. Hoffmann-La Roche, Ltd.; Grifols; Hologic Inc. (Gen Probe); Illumina, Inc.; QIAGEN; Siemens Healthineers AG; and Sysmex Corporation.
Polaris Market Research has segmented the molecular diagnostics market report on the basis of product, test location, technology, application, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Instruments
Reagents
Others
By Test Location Outlook (Revenue, USD Billion, 2020-2034)
Point of Care
Self-test or OTC
Central Laboratories
By Technology Outlook (Revenue, USD Billion, 2020-2034)
Polymerase Chain Reaction (PCR)
PCR, by Procedure
Nucleic Acid Extraction
Others
PCR, by Type
Multiplex PCR
Other PCR
PCR, by Product
Instruments
Reagents
Others
In Situ Hybridization (ISH)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Chips and Microarrays
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Others
By Application Outlook (Revenue, USD Billion, 2020-2034)
Oncology
Pharmacogenomics
Infectious Disease
MRSA
Clostridium Difficile
Tuberculosis and Drug-Resistant TB
Meningitis
Gonorrhea
HIV
Hepatitis C
Hepatitis B
Others
Genetic Testing
Neurological Disease
Cardiovascular Disease
Microbiology
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa